Authors
Advertisement
Advertisement
Trending on HCPLive
1
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
2
Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab
3
Q&A: Tulisokibart Results and TL1A Inhibition in HS, With Alexa Kimball, MD, MPH
4
Risankizumab Shows Higher 3-Year Drug Survival in Psoriasis With PsA
5
